Nasdaq

Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025

Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step progressing to the istaroxime ...
Seeking Alpha

Windtree Therapeutics Initiates SEISMiC C Study of Istaroxime in SCAI Stage C Cardiogenic Shock for Planned Completion of Phase 2b and Transition to Phase 3

After successful SEISMiC A and B studies in Early Cardiogenic Shock, SEISMiC C will treat more severe SCAI Stage C cardiogenic shock to complete the assessment of the intended Phase 3 patient ...
Nasdaq

Windtree Therapeutics Advances Istaroxime Cardiogenic Shock Program with SEISMiC C Study Interim Analysis Planned for July 2025

Windtree Therapeutics, Inc. announced that it is preparing for an interim analysis of its SEISMiC C Phase 2 study of istaroxime, targeting results for July 2025. This global, placebo-controlled, ...
Business Insider

Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock

SEISMiC Extension Study results are anticipated in mid-2024 and expected to provide dose optimization for Phase 3 The Company is also progressing a parallel SCAI Stage C Phase 2 study with istaroxime ...
Business Insider

Windtree Therapeutics initiates SEISMiC C study of istaroxime

Windtree Therapeutics (WINT) announced the initiation of enrollment in the SEISMiC C trial in SCAI Stage C cardiogenic shock. This study follows the positive results in both SEISMiC A and B in SCAI ...
TCTMD

TCT 264: Improving Risk Stratification of SCAI Stages of Cardiogenic Shock With Machine Learning-Based Phenotyping

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...